
Results
9
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
9 companies
AbbVie
Market Cap: US$438.3b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$248.00
7D
-2.7%
1Y
29.5%
Merck
Market Cap: US$305.1b
Operates as a healthcare company worldwide.
MRK
US$124.03
7D
-2.2%
1Y
48.2%
Travere Therapeutics
Market Cap: US$5.3b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$56.29
7D
-2.1%
1Y
232.9%
Mesa Laboratories
Market Cap: US$528.2m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$94.95
7D
-7.4%
1Y
14.6%
Sotera Health
Market Cap: US$5.3b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$18.17
7D
1.7%
1Y
56.5%
BioLife Solutions
Market Cap: US$1.4b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$28.10
7D
1.1%
1Y
27.6%
SIGA Technologies
Market Cap: US$257.5m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.61
7D
-3.7%
1Y
-47.4%
Waters
Market Cap: US$37.0b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$373.22
7D
-1.5%
1Y
22.7%
Repligen
Market Cap: US$8.1b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$144.88
7D
2.4%
1Y
19.4%